Case report: Liver transplant recipient on dialysis for over 10 months recovered kidney function
Can a transplanted liver help a failing kidney recover after months on dialysis?
A case report describes a single liver transplant recipient with pre-transplantation acute kidney injury attributed to hepatorenal syndrome …
A patient on dialysis for over 10 months recovered kidney function after a liver transplant, challenging the belief that long-term dialysis …
Atorvastatin evaluated for dyslipidemia in children with steroid-sensitive nephrotic syndrome
Can a common cholesterol drug protect children's hearts and kidneys from a hidden danger?
A quasi-experimental study of 100 children aged 8-18 years with steroid-sensitive nephrotic syndrome and dyslipidemia evaluated the effectiv…
A common cholesterol drug called atorvastatin may help children with kidney disease reach safer heart and blood fat levels when diet alone i…
CFZ533 vs Tacrolimus in Kidney Transplant: Phase 2 Study Terminated After Interim Analysis
Did a new drug for kidney transplant patients work better than standard treatment?
A Phase 2 study comparing the anti-CD40 monoclonal antibody CFZ533 to tacrolimus for preventing organ rejection in kidney transplant recipie…
A planned five-year kidney transplant drug trial ended early after an interim look, leaving the key question about the new treatment's perfo…
TRACK trial to assess low-dose rivaroxaban for MACE in advanced CKD/dialysis patients
Can a low-dose blood thinner protect people with advanced kidney disease from heart attacks and strokes?
The TRACK trial is a global, quadruple-blind, placebo-controlled phase 3 study evaluating low-dose rivaroxaban (2.5 mg) for reducing major a…
A new global study tested whether a low-dose blood thinner safely protects people with advanced kidney disease from heart attacks and stroke…
Acthar studied in FSGS patients undergoing renal transplantation to measure recurrence rate
Can a medication help prevent kidney disease from returning after transplant?
A prospective phase 3 study enrolled 15 renal transplant recipients with primary FSGS to evaluate Acthar.
A new kidney transplant study found that Acthar medication may lower the risk of FSGS returning to the new organ, offering hope to patients …
Phase 2 Study Evaluates Abatacept for Kidney Transplant Recipients
Could a new biomarker improve kidney transplant outcomes for patients?
A Phase 2 study is recruiting 800 kidney transplant recipients to assess HLA-DR/DQ mMM scores as prognostic biomarkers.
A new kidney transplant biomarker could predict complications, while a follow-up trial tests if switching to abatacept improves function and…
PALaDIN Study: High vs. Low Dose Iron in Peritoneal Dialysis Patients
Can high-dose iron improve health for people on peritoneal dialysis?
The PALaDIN study, a phase 3 trial, is recruiting to compare high-dose and low-dose iron treatments in peritoneal dialysis patients with ana…
People on peritoneal dialysis in the UK may see better health and fewer blood transfusions if they receive high-dose iron instead of low-dos…
Phase 2 Study: ManNAc for FSGS Shows Promise in Reducing Proteinuria
Could a New Drug Offer Hope for Kidney Disease Sufferers?
A Phase 2 trial is evaluating ManNAc for primary FSGS in 30 patients. Primary endpoints include proteinuria reduction and safety. Results pe…
A new drug called ManNAc may help reduce protein loss in urine for people with kidney scarring, offering hope for those facing dialysis or t…
Phase 2 Study Evaluates Frexalimab, Brivekimig, Rilzabrutinib in FSGS and MCD
Could New Treatments Help Those Struggling with Kidney Disease?
A Phase 2a trial is assessing frexalimab, brivekimig, and rilzabrutinib for reducing proteinuria in FSGS and MCD. Primary outcome is the per…
New kidney treatments aim to reduce urine protein and improve daily life for patients with FSGS or minimal change disease.